Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback